As director for the Translational Research Institute for Space Health (TRISH), Dorit Donoviel, Ph.D., leads a $0.25B NASA-funded innovation R&D program that finds, funds and facilitates disruptive human health and performance solutions for astronauts traveling in deep space. In her previous role as deputy chief scientist of the National Space Biomedical Research Institute (NSBRI), Dr. Donoviel led both domestic and international research programs that bridged academic, industry, and government resources to deliver fast and cost-effective tangible results. She is the recipient of multiple honors including recognition from the NASA and the NSBRI Pioneer Award. A published research scientist and invited speaker, Dr. Donoviel is Associate Professor in the Department of Pharmacology and Chemical Biology and the Center for Space Medicine at Baylor College of Medicine (BCM). Before joining BCM, she led metabolism drug discovery programs at Lexicon Pharmaceuticals for 8 years. Dr. Donoviel completed a Human Frontiers postdoctoral fellowship at Mount Sinai Hospital in Toronto, Canada; holds a Biochemistry doctorate from the University of Washington in Seattle, WA; and received her baccalaureate degree in Biochemistry and Cell Biology from the University of California, San Diego in La Jolla, CA.